STOCK TITAN

Biophytis - BPTS STOCK NEWS

Welcome to our dedicated news page for Biophytis (Ticker: BPTS), a resource for investors and traders seeking the latest updates and insights on Biophytis.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biophytis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biophytis's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.04%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.26%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.26%
Tags
clinical trial
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.35%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.73%
Tags
covid-19
Biophytis

Nasdaq:BPTS

BPTS Rankings

BPTS Stock Data

4.24M
425.54M
0.09%
0.31%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
France
Paris

About BPTS

biophytis is a biotech company developping therapeutics for aging diseases. it that has been created in 2006 as a spin-off of université pierre et marie curie (paris). biophytis has developped a portfolio of drug candidates at clinical stage for the treatment of sarcopenic obesity (bio101, bio103) and dry age-related macular degeneration (bio201).